Forma Therapeutics Holdings, Inc. (FMTX)
FMTXPrice: $20.01
Fair Value: 🔒
🔒score
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatm... more
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developmen... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Frank D. Lee |
| IPO Date | 2020-06-19 | CAGR | — |
| Employees | 189 | Website | www.formatherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
FMTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $286.79M | P/E Ratio | -5.24 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1.65 |
| P/CF Ratio | -5.49 | P/FCF Ratio | — |
| EPS | $-3.82 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.3% | ROA | -0.31% |
| ROCE | -0.33% | Current Ratio | 13.86 |
| Quick Ratio | 13.86 | Cash Ratio | 2.21 |
| Debt/Equity | 0.07 | Interest Coverage | — |
| Altman Z Score | — | Piotroski Score | — |